Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, Gäbelein A, Pfeifer D, Carro MS, Weyerbrock A, Prinz M, Schnell O (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 8
Pages Range: 42214-42225
Journal Issue: 26
DOI: 10.18632/oncotarget.15031
Abstract
Glioblastoma multiforme are highly malignant brain tumours with frequent genetic and epigenetic alterations. The poor clinical outcome of these tumours necessitates the development of new treatment options. Immunotherapies for glioblastoma multiforme including PD1/PD-L1 inhibition are currently tested in ongoing clinical trials. The purpose of this study was to investigate the molecular background of PD-L1 expression in glioblastoma multiforme and to find associated pathway activation and genetic alterations. We show that PD-L1 is up-regulated in IDH1/2 wildtype glioblastoma multiforme compared to lower-grade gliomas. In addition, a strong association of PD-L1 with the mesenchymal expression subgroup was observed. Consistent with that, NF1 mutation and corresponding activation of the MAPK pathway was strongly connected to PD-L1 expression. Our findings may explain different response to PD-L1 inhibition of patients in ongoing trials and may help to select patients that may profit of immunotherapy in the future.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Heiland, D.H., Haaker, G., Delev, D., Mercas, B., Masalha, W., Heynckes, S.,... Schnell, O. (2017). Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget, 8(26), 42214-42225. https://doi.org/10.18632/oncotarget.15031
MLA:
Heiland, Dieter Henrik, et al. "Comprehensive analysis of PD-L1 expression in glioblastoma multiforme." Oncotarget 8.26 (2017): 42214-42225.
BibTeX: Download